Hoorah for some positive women's health news! A new endometriosis pill has been made available on the NHS in England, in what's being a called a “first-of-its-kind” step forward in treating the debilitating disease.

A new combination pill, relugolix–estradiol–norethisterone, has been approved for treating endometriosis on the NHS. This marks the first long-term, daily oral treatment for the condition, offering a significant advancement in endometriosis management.

The first daily pill for treating endometriosis symptoms has been approved for use on the NHS in England and Wales - but only for patients who have tried all other options. Endometriosis affects 1.5 million women in the UK, causing pain and extreme tiredness as a result of tissue similar to the womb lining growing elsewhere in the body.

A transformational new pill for treating endometriosis has been approved for use on the NHS across England. The new tablet, called relugolix-estradiol-norethisterone, has been approved by the drug regulator, National Institute for Health and Care Excellence (Nice).

A new pill designed to transform the treatment of endometriosis has been approved for use on the NHS. The combination drug could help around 1,000 women every year in England who suffer from the debilitating condition.

Gedeon Richter's drug is the only licensed GnRH antagonist option and, unlike GnRH agonists like Takeda's Prostap (leuprorelin acetate) and AstraZeneca's Zoladex (goserelin acetate) – which are only licensed for up to six months – can be taken up until menopause.

Ryeqo drug is hailed as a ‘potential step-change’ in how endometriosis is treated A new pill designed to transform the treatment of endometriosis has been approved for use on the NHS in England and Wales.

A new pill that promises to help endometriosis sufferers deal with the chronic disease’s debilitating symptoms was approved by the National Institue for Health and Care Excellence (NICE) for use on the NHS on Thursday.